A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities

NCT06047548 · Completed

Last updated 2026-05-28

This clinical trial is testing the medication LY3298176 (Tirzepatide) to see if it helps people with obesity or overweight maintain weight loss they achieved during a prior 60-week weight loss program.

Status Completed The study has finished.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 441 people

Who can join Ages 18+ · all sexes

Timeline Started 2023-09 · est. completion 2026-01

Where 20 sites · United States

What this study is testing ClinicalTrials.gov NCT06047548 ↗

Description as written by the study sponsor.

The main purpose of this study is to evaluate the efficacy and safety of tirzepatide for the maintenance of body weight reduction.

Treatments tested

Tirzepatide also known as LY3298176 Drug

Administered SC
Placebo Drug

Administered SC

Main thing measured	Percent Maintenance of Body Weight (BW) Reduction Achieved during the 60-Week Weight Loss Period
Sponsor	Eli Lilly and Company
Conditions studied	Overweight, Obesity
GLP-1 drugs	tirzepatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06047548 ↗